 | Up a level |
Number of items: 1.
Smith, M. R., Parker, C. C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., Boegemann, M., Matveev, V., Piulats, J. M., Zucca, L. E., Heidenreich, A., Kakehi, Y., Zhang, A., Krissel, H., Shen, J., Wagner, V. and Higano, C. (2018). ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041